Sustained Therapeutics is a clinical stage company utilizing advanced clinical and research expertise to develop a patented novel locally injected sustained-release drug delivery platform. This platform can deliver multiple different drugs. Our first product is a non-opioid therapeutic with the potential to provide effective, long-lasting solutions for managing both acute and chronic pain. Designed to relieve pain in a highly controlled way over longer periods with fewer side effects than current standard of care, it offers up to four weeks of pain relief from a single injection. In addition it is non-addictive, unlike opioid drugs. Sustained Therapeutics has completed a successful Phase I trial and has two Phase II trials underway, one in post-operative pain and the other in chronic pain. We anticipate completing these trials in mid-2024. A Phase II study of our second product, an oncology drug with an orphan indication, has received regulatory approval and will commence soon.